Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Recruiting 2Active not recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 4Dermatologic 2NET 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 158Pancreatic Neoplasms 148Carcinoma, Hepatocellular 127Colonic Neoplasms 79Stomach Neoplasms 58Rectal Neoplasms 58Liver Neoplasms 47Esophageal Neoplasms 46Breast Neoplasms 40Neoplasms 36Neoplasm Metastasis 35Cholangiocarcinoma 32Lung Neoplasms 23Gastrointestinal Neoplasms 20Ovarian Neoplasms 17Biliary Tract Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Esophageal Squamous Cell Carcinoma 13Uterine Cervical Neoplasms 11Gallbladder Neoplasms 10Adenocarcinoma 10Sarcoma 9Carcinoma, Renal Cell 9Adenocarcinoma Of Esophagus 9Urinary Bladder Neoplasms 8Recurrence 8Bile Duct Neoplasms 8Prostatic Neoplasms 7Gastrointestinal Stromal Tumors 7Colonic Polyps 7

Interventions

veliparib 1Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Somatostatinoma × Gastrointestinal × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡